The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Abstract excerpt

First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e. exon 19 deletions or L858R). However, acquired resistance to EGFR TKI monotherapy occurs invariably within a median time frame of one year. The most common form of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acrylamides
• Share to Aniline Compounds
• Share to Clinical Trials, Phase II as Topic